Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at RBC Capital Markets Healthcare Conference Transcript

May 21, 2019 / 12:00PM GMT
Release Date Price: $87.2
Unidentified Analyst

Dr. Baffi, I'll go ahead and actually you introduce yourself, and then maybe we can start with a quick background on BioMarin and jump into more detailed session.

Robert A. Baffi
BioMarin Pharmaceutical Inc. - EVP of Technical Operations

Sure. Nice to be here this morning. Thank you for the invitation. I'm the Executive Vice President of Technical Operations at BioMarin, responsible for overall quality, manufacturing, process sciences and engineering functions for the company. I'm responsible for producing not only our clinical products but our commercial products. We have 7 commercial products generating this year about $1.7 billion in revenue distributed in over 75 countries around the world. Mostly enzyme products, 5 enzymes and 2 small molecules. And as we get into the gene therapy discussion, we'll discuss how we've leveraged our experience in the biologics, that is the enzyme products, to really jump start our gene therapy program.

Questions & Answers

Unidentified Analyst

Perfect. Thank you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot